阿利沙坦片治疗高血压视网膜动脉硬化及对血管内皮功能、HMGB1、Ghrelin、β2-MG的影响  

Allisartan Tablet in treating hypertensive retinal arteriosclerosis and its influence on vascular endothelial function,high mobility group box-1 protein,endogenous ligand of hypothalamic growth hormone secretin receptor and β2-microglobulin

作　　者：朱铭 郑琦 黄淮 孙静 边毓尧 Zhu Ming;Zheng Qi;Huang Huai;Sun Jing;Bian Yuyao(First Department of Cardiology,Hebei Petro China Central Hospital,Langfang 065000,China;不详)

机构地区：[1]河北中石油中心医院心内一科,廊坊065000 [2]河北中石油中心医院眼科,廊坊065000 [3]河北中石油中心医院急诊科,廊坊065000

出　　处：《中国循证心血管医学杂志》2024年第6期707-710,共4页Chinese Journal of Evidence-Based Cardiovascular Medicine

基　　金：河北省廊坊市科技支撑计划项目(2017013146);2018年河北省重点研究计划项目(182777143)。

摘　　要：目的探究阿利沙坦片治疗高血压视网膜动脉硬化(HRA)以及对血管内皮功能、高迁移率族蛋白B1(HMGB1)、下丘脑生长激素促分泌素受体内源性配体(Ghrelin)、β2-微球蛋白(β2-MG)的影响。方法前瞻性选择2017年1月至2020年12月于河北中石油中心医院治疗的HRA患者320例,通过随机数字表法分为试验组和对照组(每组各160例)。试验组以阿利沙坦治疗,对照组以硝苯地平治疗。观察两组患者治疗前及治疗6个月收缩压(SBP)、舒张压(DBP)等血压指标,视网膜动脉硬化(RA)分级,血清血管内皮生长因子(VEGF)、一氧化氮(NO)及内皮素-1(ET-1)等血管内皮功能指标和血清HMGB1、Ghrelin、β2-MG水平,以及不良反应。结果治疗6个月后,试验组SBP、DBP均低于对照组[(120.65±15.62)mmHg vs.(137.76±16.14)mmHg;(86.76±9.15)mmHg vs.(92.05±9.43)mmHg,P<0.05]。试验组Scheie房角高分级占比低于对照组(P<0.05)。试验组血清VEGF、NO水平均高于对照组[(32.08±3.42)ng/L vs.(27.64±2.93)ng/L;(30.35±3.31)μmol/L vs.(26.05±2.88)μmol/L],血清ET-1、HMGB1、Ghrelin、β2-MG水平低于对照组[(84.65±8.63)ng/L vs.(91.50±9.36)ng/L;(301.64±32.39)pg/ml vs.(346.17±36.50)pg/ml;(11.86±1.37)pg/ml vs.(16.25±1.90)pg/ml;(1.79±0.19)mg/L vs.(2.11±0.23)mg/L,P<0.05]。两组不良反应发生率无差异(P>0.05)。结论阿利沙坦片治疗HRA可有效控制血压,改善血管内皮功能,降低视网膜动脉硬化分级,抑制HMGB1、Ghrelin、β2-MG生成。Objective To investigate Allisartan Tablet in treating hypertensive retinal arteriosclerosis(HRA)and its influence on vascular endothelial function,high mobility group box-1 protein(HMGB1),endogenous ligand of hypothalamic growth hormone secretin receptor(Ghrelin)and β2-microglobulin(β2-MG).Methods HRA patients(n=320)were retrospectively chosen from Hebei Petro China Central Hospital from Jan.2017 to Dec.2020,and then divided into test group and control group(each n=160)according to random digital table.The test group was treated with Allisartan Tablet and control group was treated with Nifedipine Tablet.The indexes of blood pressure including systolic blood pressure(SBP)and diastolic blood pressure(DBP),grading of retinal arteriosclerosis(RA),indexes of vascular endothelial function including vascular endothelial growth factor(VEGF),nitric oxide(NO)and endothelin-1(ET-1),levels of serum HMGB1,Ghrelin and β2-MG,and adverse reactions were observed in 2 groups before treatment and after treatment for 6 months.Results After treatment for 6 months,the levels of SBP[(120.65±15.62)mmHg vs.(137.76±16.14)mmHg]and DBP[(86.76±9.15)mmHg vs.(92.05±9.43)mmHg]were lower in test group than those in control group(P<0.05).The proportion of higher Scheie angle grade was lower in test group than that in control group(P<0.05).The levels of serum VEGF[(32.08±3.42)ng/L vs.(27.64±2.93)ng/L]and NO[(30.35±3.31)μmol/L vs.(26.05±2.88)μmol/L]were higher in test group than those in control group,and The levels of serum ET-1[(84.65±8.63)ng/L vs.(91.50±9.36)ng/L],HMGB1[(301.64±32.39)pg/ml vs.(346.17±36.50)pg/ml],Ghrelin[(11.86±1.37)pg/ml vs.(16.25±1.90)pg/ml]and β2-MG[(1.79±0.19)mg/L vs.(2.11±0.23)mg/L]were lower in test group than those in control group(P<0.05).The incidence of adverse reactions had no difference between 2 groups(P>0.05).Conclusion Allisartan Tablet,in HRA treatment,can effectively control blood pressure,improve vascular endothelial function,reduce RA grade,and inhibit generation of HMGB1,Ghrelin and β2

关 键 词：高血压 视网膜动脉硬化 血管内皮功能 阿利沙坦 

分 类 号：R544.1[医药卫生—心血管疾病]